CVAC Shares Up; CV2CoV Shows Improved Immune Response In Preclinical Study

Shares of CureVac N.V. (CVAC) are currently trading at $60.02, up $1.22 or 2.07%, with trading volume of over 518K versus an average volume of 1.27 million shares. The stock has been trading in the range of $43.00 - $151.80 for the past one year.

CureVac said its second-generation COVID-19 vaccine candidate, CV2CoV, is advancing on track to enter clinical development in fourth quarter, 2021. Also, the company remains committed to seeking regulatory approval with European Medicines agency for its first-generation COVID-19 vaccine candidate, CVnCoV.

CureVac and GSK published preclinical data, characterizing immune responses as well as the protective efficacy of CV2CoV and CVnCoV against SARS-CoV-2 challenge in non-human primates. Higher antibody neutralizing capacity was observed with CV2CoV across all selected variants, including the Beta, Delta and Lambda variants.

"In this animal model, CV2CoV is shown to induce broad antibody and cellular immune responses very similar to the breadth of the immune responses observed after infection with SARS-CoV-2," said Igor Splawski, Chief Scientific Officer of CureVac.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT